Sign in
Taking people in United StatesNo phase

Tests a device that detects melanoma cells circulating in the blood

Tests a non-invasive device that counts melanoma cells in blood in adults.

Key facts

Who runs it
Cytoastra
Where
Madison, United StatesSee the site
Trial code
Registry title
In Vivo Liquid Biopsy of Melanoma (Cytophone)
Status
Recruiting
People taking part
180 people, planned
Started
11 Feb 2025
Planned end
31 Mar 2026
Type of study
Interventional
Treatments tested
  • Cytophone
Record updated
11 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed melanoma diagnosis to test the Cytophone, a non-invasive device that counts melanoma cells in the blood.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Melanoma confirmed by tissue examination (histology). No stage is named in the record.

Main reasons for not taking part

  • Cannot give informed consent
  • Serious heart, liver, brain, hormone or other major body disease that makes the study difficult or risky
  • Ongoing serious or severe infection
  • Pregnant or breast-feeding, or planning pregnancy during the study
  • History of severe constipation

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Histological documented diagnosis of melanoma
  • Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks
  • Must be able to sit for up to 60 minutes

Who cannot take part

  • Unable to provide informed consent to participate in the study, such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study
  • Clinically relevant cardiovascular, hepatic, neurological (e.g., evidence of organic brain syndrome), endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study
  • Persistent significant or severe infection, either acute or chronic
  • Any known history of severe preexisting constipation
  • Pregnant or breast-feeding women or those who plan to become pregnant during the study
  • Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • SSM Health Dean Medical Group Specialty ServicesMadison, United StatesContact: Lisa Lepeak, MDTaking people

About the trial

What the trial wants to find out

The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume than routine blood tests. The important benefit of the Cytophone diagnosis is that the test does not require injection or any skin incision (i.e., non-invasiveness). The goal of this clinical trial is to demonstrate evidence of the capability of the Cytophone test to indicate a risk of metastasis and define CTC counts that correlate with melanoma recurrence, progression of metastatic disease, and therapy efficacy. The investigators believe that clinical trials will provide evidence that the Cytophone can diagnose risk of melanoma metastasis and recurrence earlier than existing methods.

The group in the trial

  • Cytophone applicationTreatment being tested

    It is anticipated that Cytophone diagnostic procedure will start with 30-min preparation including ultrasound imaging of an examined vessel, photo of a skin area above the vessel and quick navigation of the PAFC probe on the vessel using near-infrared viewer. After completion, the Cytophone monitoring will be conducted for 30-60 min and will include noninvasive irradiation of the vessel by a laser beam(s) using a safe for human laser energy level.

    Treatment: Cytophone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
In Vivo Liquid Biopsy for Early Detection of Metastatic Melanoma
Plain-language title
Tests a device that detects melanoma cells circulating in the bloodGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06488365, who can take part
Record updated
11 March 2025